Literature DB >> 2752420

Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression.

M Green1, M Ishino, P M Loewenstein.   

Abstract

The HIV-1 Tat protein is a potent trans-activator essential for virus replication. We reported previously that HIV-1 Tat peptides containing residues 37-48 (mainly region II), a possible activating region, and residues 49-57 (region III), a nuclear targeting and putative nucleic acid binding region, possess minimal but distinct trans-activator activity. The presence of residues 58-72 (region IV) greatly enhances trans-activation. We postulate that Tat mutant peptides with an inactive region II and a functional region III can behave as dominant negative mutants. We synthesized minimal domain peptides containing single amino substitutions for amino acid residues within region II that are conserved among different HIV isolates. We identify four amino acid residues whose substitution within Tat minimal domain peptides leads to defects in transactivation. Some of these mutants are trans-dominant in several peptide backbones, since they strongly inhibit trans-activation by wild-type Tat protein added to cells or expressed from microinjected plasmid. Significantly, trans-activation of integrated HIV-LTRCAT is blocked by some trans-dominant mutant peptides. These results suggest an attractive approach for the development of an AIDS therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2752420     DOI: 10.1016/0092-8674(89)90417-0

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  87 in total

1.  Functional dissection of the Autographa californica nuclear polyhedrosis virus immediate-early 1 transcriptional regulatory protein.

Authors:  G R Kovacs; J Choi; L A Guarino; M D Summers
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  trans-dominant inhibition of human hepatitis delta virus genome replication.

Authors:  J S Glenn; J M White
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

3.  A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency.

Authors:  S Emiliani; C Van Lint; W Fischle; P Paras; M Ott; J Brady; E Verdin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  cis expression of the F12 human immunodeficiency virus (HIV) Nef allele transforms the highly productive NL4-3 HIV type 1 to a replication-defective strain: involvement of both Env gp41 and CD4 intracytoplasmic tails.

Authors:  E Olivetta; K Pugliese; R Bona; P D'Aloja; F Ferrantelli; A C Santarcangelo; G Mattia; P Verani; M Federico
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus.

Authors:  M Federico; F Nappi; G Ferrari; C Chelucci; F Mavilio; P Verani
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1.

Authors:  Z Matsuda; X Yu; Q C Yu; T H Lee; M Essex
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

7.  Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Molecular cloning and characterization of a cellular protein that interacts with the human immunodeficiency virus type 1 Tat transactivator and encodes a strong transcriptional activation domain.

Authors:  L Yu; Z Zhang; P M Loewenstein; K Desai; Q Tang; D Mao; J S Symington; M Green
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Targeting tat inhibitors in the assembly of human immunodeficiency virus type 1 transcription complexes.

Authors:  Iván D'Orso; Jocelyn R Grunwell; Robert L Nakamura; Chandreyee Das; Alan D Frankel
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Adeno-associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells.

Authors:  B A Antoni; A B Rabson; I L Miller; J P Trempe; N Chejanovsky; B J Carter
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.